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Abstract 
Introduction  
There have been great scale-ups of antiretroviral therapy (ART) in sub-Saharan Africa recent 
years. ART is very efficient in treating HIV, but it needs to be taken with strict adherence and 
life-long. Thus, the current challenge is to keep patients in the treatment programmes.  
 
Aims 
The aim of this study was to find the proportion of patients starting ART 2012-2015 that 
remain in treatment the following four years at Dodoma Regional Referral Hospital. 
Furthermore, to find out whether patients lost to follow-up differed from patients remaining in 
care. Finally, to find out about patients´ experiences of being treated with ART.  
 
Methods 
Data was gathered from Dodoma Regional Referral Hospital´s local database concerning 
2333 patients, from 200 patient files and from 100 answered questionnaires. SPSS was used 
for analysing data.  
 
Results 
Retention in treatment was 60% one year after treatment start, with further decrease to 47% 
after four years. Patients starting ART 2012 were more likely to remain in care than patients 
starting later. Having advanced HIV classified as WHO clinical stage 3 at treatment start was 
found to be a factor that increased the risk of being lost to follow-up (OR 3.19, 95% CI 1.81-
8.59).  
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Incomplete adherence was shown in 22% of patients, where patients had missed to take at 
least one dose of ART the last four weeks before time of investigation. Side effects increased 
the risk for poor adherence. Stigma was seen; 22% of patients chose not to tell others about 
being HIV positive because of fear of being discriminated and 10% because of fear of being 
excluded from their families.  
 
Conclusions and implications 
Retention in treatment was low and needs to be increased. By inquiring for factors associated 
with being lost to follow-up patients in need of extra resources to remain in treatment could 
be identified.  
 
Keywords 
Antiretroviral therapy, retention, adherence, Tanzania.   
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Introduction 
History and epidemiology 
The first cases of AIDS (acquired immunodeficiency syndrome) were described in 1981 and 
the virus HIV (human immunodeficiency virus) causing the disease was discovered in 1983. 
By then, the disease was thought to be a threat to only special risk groups (1). Since than 
humanity has learned the hard way that AIDS in fact was a disease that could affect anyone 
and plenty of people have been affected by the epidemic. Since 1981 more than 70 million 
people have been infected by HIV and more than 35 million people have died because of 
HIV/AIDS. The current number of HIV positive people globally is estimated to 37 million, 
which corresponds to about 0.8% of the world´s adults aged 15-49 years (2). The burden of 
disease varies between countries and continents, the epidemic has been most severe in low-
income countries, especially in sub-Saharan Africa (SSA) where about two thirds of the HIV 
positive people can be found (3).  
 
One of these Sub-Saharan African countries where the epidemic has been devastating is 
Tanzania. Statistics from year 2015 show that 1.4 million people were living with HIV by that 
time in Tanzania, corresponding to an estimate of 4.7% of adults aged 15-49 years. The same 
year 36,000 people died from AIDS in Tanzania. In only Tanzania there were by 2015, 
790,000 orphans aged 0-17 years due to HIV/AIDS (4). The suffering has been tremendous 
and so has also the impact on economy and social welfare been (3).  
 
Transmission and risk groups  
The main route of HIV transmission in Tanzania is heterosexual intercourse, which is 
estimated to account for 80% of the HIV cases (5). Historically, mother to child transmission 
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has been high, but is declining and by 2016 the coverage of ART was 86% for pregnant 
women living with HIV. However, there were still 10,000 new HIV infections in children by 
2016.  
 
The Joint United Nations Programme on HIV/AIDS (UNAIDS) has identified five key 
populations where more active measures need to be taken against HIV. These populations are 
sex workers, people who inject drugs, gay men and other men who have sex with men, 
transgender people and prisoners. By the year of 2016 28% of sex workers in Tanzania were 
estimated to be HIV infected and the corresponding number in men who have sex with men 
was 18%. The remaining three key populations have no corresponding numbers registered (6).  
 
90-90-90 
UNAIDS has decided on a treatment target to succeed with ending the AIDS epidemic. It is 
called 90-90-90 and this goal shall be met at year 2020 which is part of the final goal to end 
AIDS by 2030. The goal with 90-90-90 is that by 2020: 
- 90% of all HIV positive people are to know their HIV status. 
- 90% of all people with diagnosed HIV will receive antiretroviral therapy (ART). 
- 90% of all people receiving ART will have viral suppression.  
This will sum up in that at least 73% of all people living with HIV should be virally 
suppressed (7).  
 
UNAIDS has presented data reflecting the situation in Tanzania by 2016, showing that 
Tanzania is currently at 70% knowing about their HIV status, 62% are on treatment and the 
number of virally suppressed is unknown (6). These statistics show us that Tanzania has a 
long way to go and the probability that the 90-90-90 goal will be met seems to be low. 
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However, there is definitely hope; new infections are declining and people dying of AIDS are 
significantly fewer every year (5). The factor behind these progresses and the reason that 
UNAIDS has set this ambitious goal is that there is treatment available that has been very 
successful and that treatment is antiretroviral therapy (ART) (6).  
 
Antiretroviral therapy  
Pathophysiology  
HIV is a retrovirus that exists in two subtypes; type 1 and type 2. HIV-1 is more contagious 
than HIV-2 and it is HIV-1 that is responsible for all the cases of HIV infections in Tanzania, 
therefore HIV-1 will from now on be called HIV in this report (1, 3). HIV binds to the cellular 
receptor CD4 which is found mainly on helper T-lymphocytes, commonly called CD4-cells. 
The infected CD4-cells eventually die and that makes measuring CD4 count one way to 
monitor virus activity. Being a retrovirus, HIV is able to turn its RNA into DNA through the 
enzyme reverse transcriptase. In this process there are a number of different steps that are 
targets for ART (1).  
 
Antiretroviral drugs 
There are currently six different categories of ART:  
- Nucleoside reverse transcriptase inhibitors (NRTIs) 
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
- Integrase inhibitors (II) 
- Protease inhibitors (PI) 
- Entry inhibitors (EI) (subgroups: Fusion inhibitors and Chemokine receptor antagonist) 
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These drugs are taken in different combinations, commonly three different drugs from two 
different groups (8). The first line treatment in Tanzania is tenofovir (NRTI) + lamivudine 
(NRTI) + efavirenz (NNRTI). Depending on side-effects and other impacting factors the 
treatment can be modified, the Tanzanian guidelines for treatment include multiple different 
treatment regimens, including second line treatment. In Tanzania there are ten different ART 
pharmaceuticals; six NRTIs, two NNRTIs and two PIs which are used in different 
combinations (3). This is in comparison with almost 30 different ART drugs in Sweden (9).  
 
Indication 
The indication for treatment has been changed from different levels of CD4+ cells and clinical 
stage of disease to the present regimen which is simply to treat all, regardless of CD4 count. 
After a positive HIV test the patient´s eligibility for ART will be assessed (lab tests, 
psychological factors and so on) and when everything is in order treatment will start (6). This 
treat all regimen is according to WHO´s guide lines from 2015 as part of the struggle to 
achieve the 90-90-90 goal (10). However, parts of this study will be investigating patients 
starting treatment in year 2012-2015 and by that time other guidelines were used. By then the 
indications for treatment of confirmed HIV positive adults were as follows (3): 
- CD4 count 350 cells/µL or less. 
- WHO clinical stage 3 or 4. 
- Pregnant women. 
- Breastfeeding women.  
- TB co-infected.  
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Effects of ART and resistance  
ART has been a success story. It reduces the risk of developing AIDS, prolongs life and 
decrease mother to child transmission. If the therapy is successful the viral load can be 
decreased from 10# − 10% copies/ml to less than 20 copies/ml. When virus levels decrease 
the immune system recovers and the amount of CD4+ cells increase. ART has its effect 
through stopping replication of HIV which means that the virus is unable to infect new cells. 
There are, however, cells that keeps on living infected but in a latent phase, not replicating. 
These latent cells make it impossible to completely eradicate HIV from an infected person, 
since ART can only stop new cells from being infected and not treat the already infected ones 
(1).  
 
The treatment sets high demands on the patient; it has to be taken exactly according to the 
prescription, which is daily (one, two or three times) and lifelong. Just a few missed doses and 
the virus could start replicating again, it has been shown that if less than 95% of doses are 
taken replication can occur. If replication occurs in presence of medicines resistance against 
these medicines could easily be developed. There are documented cases of resistance for all 
antiretroviral drug classes, either through therapy failure or through therapy-naïve patients 
that has been infected with drug-resistant viruses (1, 8). Given these factors it is of great 
importance that retention to treatment and adherence is absolute.  
 
Several studies from sub-Saharan Africa have showed the connections between adherence, 
virological suppression/failure and drug resistance. In a review article that includes studies 
from 18 sub-Saharan African countries where the definition of virological failure was >1000 
copies/mL, virological failure occurred in 22% of patients after six months of ART, in 24% 
after twelve months and in 33% after 24 months of ART (11). There is currently no HIV drug 
 10 
resistance surveillance system in Tanzania. However, roughly 71-90% of patients with 
virological failure have been showed to have evidence of resistance (12).  
 
Side effects 
Despite the many advantages with ART there are some disadvantages too; it can cause several 
different side effects and it is common. Among the most commonly reported are for instance 
diarrhoea, peripheral neuropathy, lipodystrophy, fatigue, headache and rash (13). Typically, 
the older drugs are the ones causing the most side effects and it is also the older drugs that 
have been the most common in low-income countries due to lower price. This has, however, 
changed during the last decade since prices on more ARTs has decreased and the possibility 
of changing drugs if side effects occur has increased (14).  
 
Factors associated with adherence 
Retention to treatment programmes is a determinant of adherence, since patients must attend 
an ART care programme to monitor their HIV clinical indicators and to receive their 
prescriptions. The coverage of ART for HIV positive people has increased a lot, the challenge 
remaining is, however, not to be underestimated and that is to have a total adherence and 
retention (15).  
 
A study from Moshi, Tanzania showed that few patients were aware of which drugs of 
treatment they have and the limited future treatment options available. Results from that study 
suggested that the patients possessing that knowledge were more likely to be adherent in their 
treatment. In conclusion, it is of importance that health care personnel educate patients in 
these aspects (16).  
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Risk factors for non-adherence to treatment in SSA have been shown to be among others (15, 
17): 
- Patients of young age (<30 years). 
- Patients with baseline WHO clinical stage 3 or 4.  
- Ambulatory and bedridden patients at baseline (compared to working or active patients). 
- Loss of body weight by more than 10% at baseline. 
- Low baseline CD4 count (<50 cells/µL).  
- Accessing care from higher level healthcare facilities.   
 
Moreover, social and behavioural factors have been showed to be of importance. A large 
study performed in SSA found the following independent factors that were associated with 
incomplete adherence: high internalized stigma, positive screen for alcohol abuse and 
consulting traditional healers due to HIV (18). Stigma associated with HIV in Tanzania is 
one of the country´s main challenges concerning HIV. Stigma is a common factor for poor 
adherence and non-retention to care (19).  
 
In addition to medical adherence, retention in care is of importance for monitoring patients 
and for ensuring on-time medical refill. Several barriers to retention have been identified. A 
study performed in eastern Africa, including Tanzania, categorizes barriers to retention in 
structural (external environment), clinic based (healthcare environment) and psychosocial 
(patient-based). This study suggest that structural barriers contribute the most to patient 
transferring without announcing it (“silent transfer”), while psychosocial barriers such as 
social and psychological ones tend to result in long-term care discontinuation (20).  
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Aim  
To my knowledge there are no reports focusing on retention, investigating predictors for poor 
adherence and ways to improve adherence done at Dodoma Regional Referral Hospital, 
which is where this report aims to fill in the blanks.  
 
The purpose of this study was to follow up how many of the patients that for the first time 
received ART in January 2012 to December 2015 at Dodoma Regional Referral Hospital that 
still remained on treatment after 1, 2, 3 and 4 years after starting treatment. Furthermore, the 
study focused on factors leading to low adherence and to leaving care and treatment.  
 
Specific Objectives 
- How many of patients starting treatment in January 2012 to December 2015 remained in 
the treatment program after 1, 2, 3 and 4 years? 
- To compare sociodemographic baseline data and medical factors between patients 
leaving the treatment program and patients remaining in care.  
- To investigate patients´ experiences of antiretroviral treatment and factors that might 
influence adherence to the treatment.   
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Material and methods 
Study setting 
This study was performed at Dodoma Regional Referral Hospital, which is a governmental 
hospital. Dodoma is the capital of Tanzania and has a population of roughly 400,000. 
Dodoma region, however, has a population of just over 2 million people. The total HIV 
prevalence in the region was estimated to 2.9% in 2012 (21). The hospital is one of the bigger 
among plenty of hospitals in Dodoma. The care and treatment clinic (CTC), where data was 
collected currently, has a cumulative number of around 9200 HIV positive patients in all ages 
that have ever been enrolled in care at the clinic. However, the number of patients that 
attended the CTC during the third quarter of 2017 was 2959 of which 69% were women and 
31% were men. Since 2004 all appointments at CTCs are free of charge and so are also all 
antiretroviral drugs, this is the case in the entire country.  
 
Patients enrolled in care at the CTC at Dodoma Regional Referral Hospital are to attend the 
clinic every other month.  
 
Study design 
There are three parts of this study, part A, B and C:  
- A retrospective cohort study (part A) with numbers of how many of the patients that 
started treatment from January 2012 to December 2015 that still remained in care after 1, 
2, 3 and 4 years.  
- A case control study (part B) where randomly sampled groups of 100 patients that remain 
in care and 100 patients that were lost to follow-up will be compared in 
sociodemographic and medical factors.  
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- A general observation study (part C) of patients attending the clinic through a 
questionnaire, which aimed to assess adherence and factors associated with it.  
 
The period of January 2012 to December 2015 was chosen due to the fact that the same 
national guidelines on HIV were applied throughout that time (which are the 2012 National 
Guidelines for the Management of HIV and AIDS). Since then the guidelines have been 
changed.  
 
Patients were supposed to come to the CTC in every two months. In case a patient did not 
present itself to the clinic within three days of the booked appointment staff from the clinic 
tried to reach that patient through telephone and if that was not successful community health 
care workers tried to get in contact with the patient physically for getting the patient back in 
care. If none of these two methods were successful and the patient did not show up at the 
clinic in three months after the missed appointment the patient was labelled “lost to follow-
up” (LTFU).  
 
Some data about patients were registered in Dodoma Regional Referral Hospital´s local 
database. From that database, the quantitative data being used for part A; assessing retention 
to treatment was retrieved. All the data needed for assessing retention was present in the 
database. However, data for part B; the comparison between the patients remaining in care 
and the ones lost to follow-up was retrieved from the patients´ medical files that were 
physical paper files.  
 
Files for patients still in care and for patients that has been lost to follow-up were kept in 
different rooms at DRRH. One hundred files for patients in care and 100 files for patients lost 
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to follow-up were randomly chosen through convenient sampling. (Not all files were kept and 
that was the reason for the convenient sampling. Random generator could not be used in a 
doable way since not all the files were kept and there was no register over the files. The ones 
that were present were the ones we had to use and, therefore, it was decided that convenient 
sampling should be used). When a file had been used or just controlled for inclusion criteria it 
was put back at a special place to avoid getting data from those files twice.  
 
Inclusion criteria for the database collection (part A) were all patients at the clinic who were 
HIV positive and started ART between January 2012 and December 2015. The same applied 
for part B (the comparison of the medical files) but in addition fort part B inclusion criteria 
were also that patients had to be of age 18 years or older. The data used for part A included all 
patients in all ages and it was impossible to sort out only patients 18 years and older, therefore 
all ages were included in part A. The definition of lost to follow-up or dropping out of the 
program was, as mentioned above, for a patient not to show up at the CTC for three 
consecutive months after a missed appointment.  
 
Among the files for the retained patients, files were found that indicated that the patients had 
been lost to follow-up but were now back in care, these files were excluded.  
 
The hospital does not automatically get information about when a patient belonging to the 
hospital dies. If a patient dies in care, that patient´s file is taken away from the other ones. 
However, if a patient dies out of care and no relative informs the hospital about it and 
community health care workers do not get the information that patient would be lost to 
follow-up. The same applies for patients transferring. If it is an official transfer the hospital 
will send the file to the new hospital, but if it is a “silent transfer” (where the patient change 
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hospitals without announcing it to the old one) and the hospital fail to reach the patient this 
would also be a case of false labelling of lost to follow-up.  
 
A general observation of the people presenting to the clinic was made through a questionnaire 
(part C), which aimed to assess the patients´ experience of the treatment, adherence and 
factors associated with adherence. The questionnaires were handed out to patients that 
presented to the clinic during seven days in October 2017. The goal was to get 100 answered 
questionnaires, which was met during this period of time. 
 
The questionnaire was created by using some questions from a present questionnaire (from a 
previous degree project made by Ebba Niméus and Emma Bokström, named “Reasons behind 
interrupted antiretroviral treatment in rural Tanzania”) and by creating some new questions. 
The questionnaire was then translated into Swahili by a medical doctor. Along with the 
questionnaire the patients got written information about the study and that answering was 
voluntary and anonymous.  
 
A pilot was made where ten questionnaires were handed out to patients. After the pilot one 
question was changed to make it more understandable. The results from the pilot 
questionnaires were not included in the results of this study.  
 
Inclusion criteria in part C were all patients presenting to the clinic with the age 18 years and 
above during seven days in October 2017 that had been treated with ART for at least six 
months. When patients arrived at the clinic their medical files were controlled for if they had 
been on ART for six months or more, if they had they were asked if they could fill in the 
form. A total of four patients were not willing to participate, giving lack of time as reason.  
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The literate patients answered the questionnaires by themselves but were informed of whom 
to ask for clarifications if necessary. The not literate patients got help from CTC personnel 
with reading the questions.  
 
All in all, 103 questionnaires were distributed and 100 answered questionnaires were 
collected. The remaining three disappeared after being distributed, which was thought to be 
because of lack of time before the doctor´s appointment.  
 
Statistical methods  
All collected data was registered in Excel files. These files were later on imported to the 
statistics programme SPSS Statistics version 25. Calculations and graphs were then made 
through using SPSS Statistics. Statistical calculations used were multivariate logistic 
regression, Fisher´s exact test, z-test and Mann-Whitney U test. The multivariate regression 
analysis was performed on baseline variables that had a p-value of 0.1 or less and was 
calculated with 95% confidence intervals. Missing values were always excluded from 
statistical calculations.  
 
  
 18 
Ethics 
All patients participating in the questionnaire received written information about the study 
stressing that participation was voluntary and anonymous. There was no way of identifying 
patients´ identity through the questionnaires. The data retrieved in the file study was 
confidential with no collection of personal information and the integrity of the patients was 
respected. Ethical approval for this study was given by the Head of Dodoma Regional 
Referral Hospital. 
 
The study could be interpreted as a part of quality assurance work, where the data being used 
is already available. That kind of work would in many countries (including Sweden) not 
require ethical approval, on the contrary it is something the hospital is required to do. This 
would not be considered research and would, according to Tanzanian law, not require 
Research Clearance or Research Permit (22). Some could however argue that the 
questionnaire handed out is beyond this quality assurance work. However, the questionnaire 
aimed to find out the patients´ experiences of their care and treatment. Patients filled in 
questionnaires while waiting for their doctors´ appointments, they were not asked to come 
earlier to the clinic or to stay after their appointments. This means that the study did not claim 
any additional time from the patients.  
 
The Tanzanian supervisors for the project were in charge over getting the ethical approvals 
demanded by Tanzanian law for conducting the study. Their assessment was that this study 
was not research, therefore, it did not require any extra approvals than from the Head of the 
hospital.   
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Results 
 
Part A - Total retention in care 
The study population in this part consisted of 2333 patients who started antiretroviral 
treatment (ART) between January 2012 and December 2015 at Dodoma Regional Referral 
Hospital (DRRH) or another hospital but later transferred to DRRH. All patients, in all ages, 
were included. Table 1 shows yearly retention rates in care of all these patients. 
 
Table 1. Total retention of patients after 1, 2, 3 and 4 years for all patients starting antiretroviral therapy (ART) during the 
years 2012-2015. 
Time after ART start 
(years) 
N patients starting ART during 
cohort years adjusted for transfers 
N patients still in 
care 
Percentage CI (95%) 
1  2333 1402 60.1 58.1-62.1 
2   2209 1146 52.9 50.8-55.0 
3  1591 766 48.1 45.7-50.6 
4 1030 489 47.5 44.4-50.5 
 
The proportion of patients remaining in care was 60% after one year with further decrease the 
following years, see table 1. In addition to that, there was a tendency for the retention 
proportion to fall for every passing year of ART start which is demonstrated by figure 1. 
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Figure 1. Retention in care by follow-up year and by year of starting antiretroviral therapy (ART). The data in Dodoma 
Regional Referral Hospital´s database covered statistics until August 2017. Chart is calculated based on all 2333 patients. X= 
p<0.05.  
 
The proportion of patients remaining in care after one year was significantly higher for 
patients starting treatment in 2012 with 66.4% (95% CI 62.3-70.5) compared with 54.9% 
(95% CI 50.8-58.9) in 2014 and 57.6% (95% CI 53.7-61.5) in 2015. At two years follow-up, 
there was a significantly higher proportion of patients remaining that started treatment in 2012 
with 56.1% (95% CI 52.0-60.2) compared with 46.8 (95% CI 42.8-50.8) with starting in 
2014. The same applied for follow-up year three with 51.9% remaining (95% CI 47.7-56.0) of 
patients starting ART in 2012 and 41.7% (95% CI 36.9-46.6) of patients starting in 2014. 
  
x 
 
x 
x 
x 
x 
x 
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Part B - File study 
Demographics 
Through file studies 200 patients were included in this part of the study, 100 that were already 
labelled lost to follow-up and 100 that remained in care. Table 3 present the characteristics of 
the participants. Table 3 shows that married patients had a greater probability to remain in 
care than patients with another civic status (p=0.019).  
 
Table 2. Demographic characteristics of the 200 participants in the file study. P-values calculated with Fisher´s exact test.  
 
Demographics  Lost to 
follow-up 
n 
(n=100) 
In care 
n 
(n=100) 
Total 
n 
P-
value 
Sex Women 65 71 136 
0.45 Men 35 29 64 
Age (years) 18-25 9 3 12 
0.053 
26-30 16 18 34 
31-35 24 14 38 
36-40 21 15 36 
41-45 6 12 18 
46-50 11 13 24 
51-60 9 21 30 
61-70 3 4 7 
>70 1 0 1 
Marital status Married 38 56 94 
0.019 
Cohabiting 2 0 2 
Single 25 11 36 
Divorced/ 
separated 
21 17 38 
Widower 11 11 22 
Missing 
value 
3 5 8 
Total number 
of patients 
 100 100 200  
 
 
 
As seen in table 3, patients working at baseline were more likely to remain in care than 
patients that were either bedridden or ambulatory (p=0.010). There was a tendency for 
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remaining patients to have lower WHO clinical stage at baseline than patients lost to follow-
up (p=0.059).  
 
Table 3. Medical status of the participants at baseline and at one year follow-up. P-values calculated with Fisher´s exact test 
except for value marked with * where p-value is calculated with Mann-Whitney U test. 
Baseline  1 year follow-up 
  Lost to 
follow-up 
n 
(n=100) 
In care 
n 
(n=100) 
P-value Lost to 
follow-up 
n (%) 
(n=48) 
In care 
n (%) 
(n=100) 
P-value 
Functional 
status 
Working 74 90 
0.010 
47 (98) 100 
(100) 
0.324 
Bedridden 4 1 0 0 
Ambulatory 22 9 1 (2) 0 
WHO clinical 
stage 
1 8 8 
0.059 
5 (10) 8 (8) 
0.44 
2 24 40 9 (19) 34 (34) 
3 51 34 29 (60) 38 (38) 
4 17 18 5 (10) 20 (20) 
CD4 count 
(cells/µL) 
0-50 12 17 
0.52 
2 (4) 1 (1) 
0.674 
51-100 17 14 1 (2) 3 (3) 
101-150 9 10 2 (4) 5 (5) 
151-200 8 18 1 (2) 4 (4) 
201-250 11 11 3 (6) 5 (5) 
251-300 12 11 2 (4) 7 (7) 
301-350 8 4 2 (4) 5 (5) 
>350 12 11 3 (6) 17 (17) 
Missing value  11 4 32 (67) 53 (53) 
Median CD4 count (cells/µL) 195 171 0.327* 254 295 0.361* 
Signs/Symptoms Experiencing 
symptoms 
   15 (31) 24 (24) 
0.426 
No symptoms    33 (69) 76 (76) 
TB 
positive/negative 
Negative    45 (94) 78 (78) 
0.019 
Positive    3 (6) 22 (22) 
TB=tuberculosis. WHO clinical stage 1=Asymptomatic HIV infection or consistent generalized lymphadenopathy. WHO 
clinical stage 2=HIV infection causing light weight loss (<10%) or milder opportunistic infections e.g. seborrheic dermatitis 
or herpes zoster. WHO clinical stage 3=HIV infection causing severe weight loss (>10%) or more advanced opportunistic 
infections e.g. pulmonary TB and oral candidiasis. WHO clinical stage 4= HIV infection causing wasting syndrome or 
advanced opportunistic infections such as pneumocystis pneumonia or Kaposi´s sarcoma.  
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Table 4. Antiretroviral therapy (ART) of the patients at baseline and one year follow-up. P-values calculated with Fisher´s 
exact test.  
Baseline  1 year follow-up 
  Lost to 
follow-up 
n 
(n=100) 
In care 
n 
(n=100) 
P-value Lost to 
follow-up 
n (%) 
(n=48) 
In care 
n (%) 
(n=100) 
P-value 
ART start year 2012 28 14 
0.068 
12 (25) 14 (14) 
0.406 
2013 32 31 13 (27) 31 (31) 
2014 22 32 15 (31) 32 (32) 
2015 18 23 8 (17) 23 (23) 
ART 
combination 
regimen 
No ART 0 0 
0.11 
2 (4) 0 
0.075 
1g 36 53 17 (35) 52 (52) 
1e 24 16 11 (23) 27 (27) 
1f 2 1 2 (4) 1 (1) 
1b 10 12 4 (8) 12 (12) 
1h 1 0 1 (2) 0 
1c 27 18 10 (21) 16 (16) 
2nd line 0 0 1 (2) 2 (2) 
Treatment 
supporter 
Yes 93 95 
0.77 
44 (92) 95 (95) 
0.472 
No 7 5 4 (8) 5 (5) 
ART status Continue    39 (81) 96 (96) 
0.006 Change    7 (15) 4 (4) 
Stop    2 (4) . 
Reasons for 
changed ART 
Out of stock    1 (2) . 
1.000 
Poor 
adherence 
   1 (2) . 
Side effects    1 (2) . 
Treatment 
failure, 
immunological 
   2 (4) 3 (3) 
Not specified    1 (2) . 
Anemia    1 (2) . 
Rash    1 (2) . 
Other reason    1 (2) 1 (1) 
Missing value 
(=no 
changes) 
   39 (81) 96 (96) 
Assessed ART 
adherence 
status* 
Good     35 (73) 93 (93) 
0.002 
Poor    13 (27) 7 (7) 
*) Assessed ART adherence status is assessed during the patient´s clinic appointment by a medical doctor. No forms are 
used, it is the doctor´s personal assessment based on conversation with patients. ART=Antiretroviral Therapy. 1g) 
tenofovir+lamivudine+efavirenz, 1e) tenofovir+emtricitabine+efavirenz, 1f) tenofovir+emtricitabine+nevirapine, 1b) 
zidovudine+lamivudine+nevirapine, 1h) tenofovir+lamivudine+nevirapine, 1c) zidovudine+lamivudine+efavirenz.  
 
At one year follow-up, as seen in table 3, a bigger proportion of patients remaining in care 
was positive for tuberculosis than patients lost to follow-up (p=0.019). After one year of 
treatment 15% of the patients lost to follow-up had changes in their ART compared to 4% of 
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the patients remaining in care (p=0.006). Table 4 shows that 27% of patients lost to follow-up 
were assessed to have poor treatment adherence whereas the corresponding percentage was 
7% for patients remaining in care (p=0.002).  
 
At two years follow-up 70% of “lost to follow-up patients” had their disease classified as 
WHO clinical stage 3 which was significantly higher than the patients remaining in care 
where the corresponding number was 39% (p=0.028). In addition, at three years follow-up 
29% of the patients lost to follow-up experienced symptoms compared to 8% of the remaining 
patients (p=0.030). 
 
At two years follow-up 52% of patients remaining in care were treated with tenofovir + 
lamuvidine + efavirenz (TDF+3TC+EFV) which was significantly higher than the 
corresponding 23% of the lost to follow-up patients (p=0.002). This also applied for follow-
up year three, where 31% of patients remaining in care and none of the lost to follow-up 
patients were treated with TDF+3TC+EFV (p=0.007). At two years follow-up 13% of lost to 
follow-up patients got their ART changed which was a significantly higher proportion 
compared to 1% of remaining patients that to a greater extent continued with the same 
treatment (p=0.011). This also applied for follow-up year three, where 36% of lost to follow-
up patients stopped their treatment (mainly motivated by poor adherence) compared to none 
of the remaining patients (p<0.001). Finally, at three years follow-up the proportion of 
patients with assessed poor adherence status were 24% in the lost to follow-up group but none 
in the group with patients remaining in care (p=0.001).  
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Regression analysis  
Table 5 demonstrates that being working at start of ART was linked to lower risk of being lost 
to follow-up (OR 0.332). Also, advanced HIV with WHO clinical stage 3 increased the risk of 
being lost to follow-up.  
 
Table 5. Multivariate logistic regression analysis of baseline patient factors. Analysis performed for all baseline patient 
factors with p <0.1. Values are predicted for getting lost to follow-up. Last value in all categories was used as reference. 
  OR 95% CI P-value  
Age (years)  0.971 0.941-1.003 0.073 
Marital status Married 0.516 0.180-1.480 0.219 
 Cohabiting NA NA NA 
 Single 1.914 0.530-6.908 0.322 
 Divorced/ 
separated 
0.680 0.199-2.325 0.538 
 Widower   0.092 
Functional status Working 0.332 0.124-0.887 0.028 
 Bedridden 5.211 0.401-67.719 0.207 
 Ambulatory   0.018 
WHO clinical 
stage 
1 2.160 0.520-8.973 0.289 
 2 1.040 0.364-2.977 0.941 
 3 3.185 1.181-8.589 0.022 
 4   0.017 
ART start year 2012 1.799 0.616-5.255 0.283 
 2013 1.130 0.435-2.939 0.801 
 2014 0.618 0.238-1.600 0.321 
 2015   0.182 
ART=Antiretroviral Therapy. NA=Not Applicable. For explanation of WHO clinical stages se text under table 3. 
 
Part C - General observation through questionnaire 
This part of the study is a general observation of 100 patients presenting to the Care and 
Treatment Clinic that filled in a questionnaire. All patients that were willing to participate, 
aged 18 years or more and that had been on ART for at least six months were included.   
 
  
 26 
Demographics  
The study population in the questionnaire part of the study consisted of 100 patients, who all 
filled in the questionnaire. Of these 63% were women and 37% were men. Mean and median 
age in study population was 44 and 42 years.  
 
Table 6. Demographic characteristics of the 100 patients answering the questionnaire.  
 n  
(n=100) 
Sex Women 63 
Men 37 
Age (years) 18-25 4 
26-30 6 
31-35 9 
36-40 18 
41-45 24 
46-50 7 
51-60 18 
61-70 10 
>70 1 
Missing value 3 
Marital status Married 28 
Long term 
relationship 
6 
Single 23 
Divorced 18 
Widower 25 
Level of 
education 
Never been to 
school 
10 
Primary school not 
finished 
2 
Primary school 65 
Secondary school 17 
University/College 5 
Missing value 1 
Current 
social 
situation 
Employed 13 
Self-employed 51 
Not employed 25 
Student 3 
Other grant 4 
Missing value 4 
Religious 
affiliation 
Christian 76 
Muslim 22 
Missing value 2 
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The earliest year of HIV diagnose in the study population was 1995 and the latest 2016. Mean 
year of diagnose was 2010 and median 2011. The earliest start of treatment was 1996 and 
latest 2017, with a mean year of 2011 and median 2012.  
 
Table 7. Medical factors of the 100 participants in the questionnaire study.  
 n  
(n=100) 
Experienced health 
status before 
treatment start 
1 (Very poor) 40 
2 20 
3 13 
4 15 
5 (Excellent) 12 
Experienced health 
status currently  
1 (Very poor) 3 
2 0 
3 7 
4 26 
5 (Excellent) 63 
Missing value 1 
Prescribed doses/day One  56 
Two 44 
Missed medicine 
doses last 28 days 
0 74 
1-2 14 
3-4 4 
5-6 0 
7-10 1 
More than 10 2 
Missing value 5 
Ever 
interrupted/stopped 
treatment 
Yes 7 
No 90 
Missing value 3 
 
 
Patients were asked to fill in their self-experienced health status before treatment start and 
currently (which corresponds to after at least six months of treatment). This was made 
through marking a number on a scale from one to five, where one represented very poor and 
five represented excellent, the results are shown in table 7. Health status before start of ART 
was filled in by all patients and resulted in a mean value of 2.39 and median value of 2. 
Health at time of investigation was filled in by 99 (99%) of patients and issued in a mean and 
median value of 4.47 and 5. Women had a significantly higher median value of 2 before 
treatment start than men with a value of 1 (p=0.042, calculated with Mann-Whitney U test). 
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There was however no significant difference in current health status between women and 
men.  
 
Adherence in treatment 
Patients were questioned about whether they had missed to take any doses of ART in the last 
four weeks or not, 95 patients out of 100 answered the question, 22% stated that they had 
missed to take at least one dose. No significant difference was found between men and 
women in number of missed ART doses the last 28 days.  
 
Patients were asked what the reason was if they ever missed to take their medicine, 46 
patients did not fill in any of the reasons and 56 patients filled in one or more alternative. The 
distribution of the answers of those 56 patients is shown in figure 2. 
 
Figure 2. Reasons given by patients for ever forgetting to take medicine. Chart is based on 63 answers given by 56 patients.  
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Answers from men and women did not differ significantly. However, patients that had missed 
any doses the last four weeks did to a significantly higher proportion (10%) answer that they 
wanted to avoid side effects than patients that had not missed any doses (0%) (p=0.047).  
 
Patients were also asked what they thought could be done to prevent them from missing to 
take medicine or to not interrupt the treatment. The answers were not significantly different 
between men and women nor between patients with or without missed doses the last four 
weeks. There were 47 patients stating that they agreed with one or more of the alternatives 
and 53 patients did not tick any of the alternatives. These answers are showed in figure 3.  
 
Figure 3. Factors that patients think could help preventing missing to take medicine or interrupting the treatment. Chart is 
based on 64 answers given by 47 patients.  
 
Patients were also asked what they believed was going to happen if they do not take their HIV 
medicine regularly, 93 answers were registered and 7 were missing. There were three 
alternatives given and the percentages of answers given were distributed as follows: 8% 
“nothing will happen”, 45% “I will feel worse” and 47% “after some time the medicine will 
no longer have any effect”.  
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Experience of antiretroviral treatment  
Furthermore, patients were questioned about if they have experienced any positive effects 
since they started ART. There were five alternatives and 96 out of 100 patients gave one or 
more answers to the question. Answers were distributed as seen in figure 5. No significant 
differences between men and women or between patients with or without missed doses the 
last four weeks were found.  
 
Figure 5. Patient-experienced positive effects since start of ART. Chart based on 144 answers given by 96 patients.  
 
Patients were also asked for experienced negative effects since they started ART. There were 
61 patients stating that they had experienced at least one of the alternatives and 39 patients 
stating that they had none of the listed negative effects. A significantly higher proportion of 
the women (24%) had experienced weight loss than the men (5%) (p=0.025). Also, regarding 
patients that had missed at least one dose the last four weeks they were to a significantly 
higher proportion experiencing loss of appetite and headache than patients that had taken all 
doses (p=0.012 respectively p=0.013) which is showed in table 8.  
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Table 8. Patient-experienced negative effects since start of antiretroviral treatment (ART), answers categorized after if patient 
had missed to take any doses of ART the last four weeks or not. Table based on answers of 95 patients. Multiple answers 
were allowed. P-values calculated with Fisher´s exact test.  
 
 Patients with 
no missed 
doses 
n (%) 
(n=74) 
Patients with 
missed doses 
n (%) 
(n=21) 
P-value 
Less energy  4 (5) 4 (19) 0.069 
Sleeping disturbances  9 (12) 1 (5) 0.450 
Loss of appetite  7 (9) 7 (33) 0.012 
Feeling depressed  7 (9) 3 (14) 0.687 
Less interest in sex  12 (16) 1 (5) 0.285 
Diarrhoea 2 (3) 1 (5) 0.532 
Headache  5 (7) 6 (29) 0.013 
Skin rashes  8 (11) 3 (14) 0.703 
Losing weight  10 (14) 4 (19) 0.503 
Thinner face  1 (1) 1 (5) 0.395 
Slim legs  3 (4) 1 (5) 1.000 
More abdominal fat  6 (8) 1 (5) 1.000 
Absent or abnormal 
sensation in feet  5 (7) 2 (10) 0.648 
None  32 (43) 5 (24) 0.132 
 
Furthermore, patients were asked what gives them motivation to take their medicines. Table 9 
shows the result. There was no significant difference between answers from women and men.  
 
Table 9. Patients´ given motivations for continuing to take their ART. Patients were asked to answer in their own words, the 
answers were then divided in to the categories beneath. There were 12 missing answers and 88 patients that answered the 
question. 
 n (%) 
To have a good health  34 (39) 
To live a good life  28 (32) 
To live a long life 16 (18) 
To have strength for work  11 (13) 
My disease makes it necessary to 
take the medicine  
8 (9) 
It is good for me 10 (11) 
To be able to fulfil my dreams  3 (3) 
To stay happy 3 (3) 
Other reason 14 (16) 
 
Social support  
Patients were questioned about who they had told about their HIV status, answers are 
presented in table 10. The proportion of men that informed their fathers about their HIV status 
was 61% which was significantly higher than the 39% of the women (P=0.030). A trend of 
more men (41%) than women (25%) informing their partners was seen (p=0.124). The most 
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common person to inform was sister or brother. It is however not entirely sure to be the case; 
in Swahili, the words for sister and brother could also describe a woman or man in general 
(often that you are related to or close with).  
Table 10. Information given by patients about who they have informed about their HIV status, answers shown divided by 
sex. Table based on 187 answers given by all 100 patients, multiple answers were allowed. P-values calculated with Fisher´s 
exact test.   
 
 Women 
n (%) 
(n=63) 
Men n 
(%) 
(n=37) 
P-value 
Partner 16 (25) 15 (41) 0.124 
Mother 24 (38) 13 (35) 0.832 
Father 7 (11) 11 (30) 0.030 
Sister or brother 30 (48) 17 (46) 1.000 
Children 23 (37) 15 (41) 0.831 
Friends 6 (10) 6 (16) 0.352 
None 2 (3) 2 (5) 0.625 
 
Moreover, patients were questioned about reasons for not informing people about being HIV 
positive. Answer frequency of the alternatives were distributed in accordance to table 11. 
There were no significant differences in the answers seen to sex nor if patients had missed to 
take medicine the last four weeks or not.  
 
Table 11. Reasons for patients not to inform people about being HIV positive. There were 98 answers given by 82 patients, 
multiple answers were allowed. 18 patients did not fill in any alternative.  
 n (%) 
I am afraid my partner would leave me  4 (5) 
I am afraid my partner would not be 
intimate with me  
4 (5) 
I am afraid my family would exclude me  10 (12) 
I am afraid my friends would exclude me  5 (6) 
I am afraid I would lose my job 1 (1) 
I am afraid I would be discriminated  22 (27) 
I feel ashamed that I have HIV 6 (7) 
Nobody else needs to know 36 (44) 
Other reason 10 (12) 
 
Finally, patients were asked if the people they had informed about being HIV positive gave 
them support. Answer frequency was 100%, 76% of patients stated that they got support and 
16% that they did not. Moreover, 2% stated that the people they informed gave them more 
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problems than support. In addition, 4% answered that they had not informed anybody about 
their HIV status. Finally, 2% filled in that they had no answer.  
 
Discussion 
We found that only 60% of patients starting antiretroviral therapy (ART) at Dodoma Regional 
Referral Hospital (DRRH) January 2012 to December 2015 remain in care one year after their 
treatment start. Having advanced HIV classified as WHO clinical stage 3 at start of treatment 
increased the risk of leaving care and treatment.  
Demographics  
The file study (part B) included 200 patients of which 68% were women and 32% were men 
and the study population of 100 patients filling out the questionnaire (in part C) consisted of 
63% women and 37% men. This corresponds well to the proportions at the Care and 
Treatment Clinic (CTC) at DRRH, where there were 69% women and 31% men visiting the 
last three months. In Tanzania in general 57.7% of the HIV positive adults are estimated to be 
women and 42.3% men (4), that does not however mean that the percentage of people in care 
are the same. A study performed in, among other east African cities, Morogoro in Tanzania 
had a percentage of 69.1% women and 30.9% men when including all patients at that hospital 
(20). In conclusion, fewer men than expected (when looking at numbers of HIV positive men) 
attended clinics. One factor behind this could be that men, due to stigma, send their wives or 
female partners to receive medicine for them. In addition, male sex has been shown to be a 
risk factor for leaving treatment programmes in several studies performed in east Africa (15).  
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Retention in care 
This study found a surprisingly low proportion of patients remaining in treatment after one 
year, with only 60.1% remaining after one year with further decrease to 47.5% after four 
years. A study, performed in Tanzania and other east African countries, with more than 
18,000 patients enrolled showed a retention of 67% after two years of treatment but only 26% 
were actually lost to follow-up, others had transferred or died. Adjusted for transfers and 
death in that study results in 74% of patients remaining in care after two years of treatment, 
which corresponds to 52.9% in our study (20). Another study performed on data from 101 
Tanzanian clinics showed that 18% of patients were lost to follow-up after one year of 
treatment and 36% after three years of treatment (23). 
 
This study showed that the proportion of patients remaining in care was significantly higher 
for patients starting ART in 2012 compared to 2014. In addition, there was a tendency for 
retention proportions to be lower for every passing year of ART start from 2012 to 2015. This 
is in contrast to other studies that have shown improvement in retention over time (24, 25). 
One of the underlying reasons for the decrease could be that the years before 2012 the CTC at 
DRRH received economical donations and health care workers from Italy as a part of a 
project to improve their healthcare for HIV positive patients. This project was ended in 2012 
and the CTC does not receive Italian contributions anymore. Lack of resources could, of 
course, make it difficult to keep the same standard as before and might be what happened in 
this case.  
 
Factors linked with being lost to follow-up  
The patients lost to follow-up were on median 36 years old compared to 42 years for patients 
remaining in care (p=0.009). This suggests that a lower age increases the risk of being lost to 
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follow-up. The result is in line with other studies from Tanzania and other countries, where 
low age has been identified as one of the main risk factors for becoming lost to follow-up (15, 
26).  
 
Furthermore, having advanced HIV with the disease classified as WHO clinical stage 3 
increased the risk of being lost to follow-up (OR 3.19, 95% CI 1.18-8.59). Having a higher 
WHO stage equals a poorer health status and has been shown to increase the risk of leaving 
treatment in previous studies (15, 17). Patients with a more advanced HIV are obviously more 
likely to die than patients with a less severe HIV and this could be one explanation behind the 
result. The results emphasize the importance of early detection and treatment of HIV.  
 
After one year of treatment fewer patients lost to follow-up (LTFU) had tuberculosis (TB) 
than remaining patients. This could be connected to the fact that TB positive patients might 
have had additional visits at the clinic and staff might have stressed the importance of treating 
both diseases with good adherence. In Tanzania, the aim is to manage coinfections of HIV 
and TB integrated, which repeatedly has been shown to be effective in previous studies, this 
could also be a factor behind the result (3, 27).  
 
Moreover, patients labelled LTFU were more likely to have their treatment adherence 
assessed as poor than patients remaining in care. This appears to be a reasonable result. The 
question is however why not more of the LTFU patients than 27% after one year of treatment 
and 24% after three years were assessed to have bad adherence? Maybe it reflects the actual 
situation, but it would seem natural that many patients might, as a pre-stage, have a poor 
adherence before leaving treatment. Patients that were identified to have poor adherence 
status need extra support to make sure they improve their adherence.  
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Further findings suggest that patients experiencing symptoms during the following years after 
treatment start are more likely to be LTFU. (Symptoms included both adverse reactions and 
HIV related symptoms. Among the most common were cough, rash, headache, abdominal 
pain and skeletal pain). This reasonable result confirms what previous studies have shown; 
that a patient experiencing symptoms (both side effects and HIV related symptoms) after 
starting treatment is less likely to have a complete adherence and to remain on treatment (13, 
28). A study from, among other countries Tanzania, shows that side effects are common 
factors for incomplete adherence and in the study every additional symptom increased the 
odds of incomplete adherence by 12% (13). Sometimes side effects of ART can be more 
disabling for patients than the disease appeared to be, this makes it difficult for patients to put 
out with side effects and keep a good adherence in treatment. This also comes hand in hand 
with the results in this study showing that LTFU patients also were more likely to have had 
changes done in their ART. Some of them due to stock out, some because of immunological 
treatment failure, side effects or poor adherence. This appears to be a reasonable result; poor 
adherence and bad retention is coupled. Also, statistics tend to show that the longer patients 
stay on ART, the fewer side effects, thus the side effects tail away. This is likely to be false, 
since patients experiencing side effects are prone to quit therapy. Being one of the main 
factors behind poor adherence side effects are to be taken seriously and should be requested at 
patient´s appointments. Furthermore, treatment with tenofovir + lamuvidine + efavirenz 
(TDF+3TC+EFV) was the best (of the combinations they had access to in Tanzania in 2012-
2015) for keeping patients in care and treatment. This combination is known to have fewer 
side effects than many other combinations and is therefore linked to better adherence and 
retention.  
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General observation among patients on treatment through questionnaire  
Patients´ self-experienced health status on a scale of one to five was increased from a mean of 
2.39 before ART start to 4.47 at the point of investigation. Since ART has been successful in 
decreasing the burden of disease, this result was not unexpected but yet satisfactory. Women 
declared a higher health status before treatment than men, but after at least six months of 
treatment the difference had evened out. It has been showed before that men enter health care 
with a more advanced disease then women (29). This could be due to different explanations; 
men are, unlike women, not screened because of pregnancy and they do not partner test to the 
same extent as women (30). The study population in this part of the study was quite 
homogenous, where all patients were attending the clinic and had a rather high adherence to 
treatment, which goes hand in hand with the good results of ART seen in rise of self-
experienced health status.  
 
Adherence to treatment 
We found that 22% of the patients reported missing at least one dose of ART the last four 
weeks. This was lower than findings in a study performed in Tanzania, Uganda and Zambia, 
where 58% of patients reported taking less than 100% of their ART doses the last 30 days 
(18). If the results from this study do not entirely reflect the truth, this difference could be due 
to the fact that patients were anxious to fill in the right answer because they were afraid their 
treating doctor would find out and disapprove. However, the result could also be correct. In 
that case, one reason for a higher adherence than the other study could be that the study 
population, as written before, was a group of patients that actually had a good retention. 
 
When patients were asked about what could prevent them from missing doses, the most 
common answers were: fewer tablets, longer opening hours at the clinic, less side effects and 
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possibility to get medicine closer to home. Fifty-six percent of the patients have a single dose 
per day regimen and the rest had two doses per day. There is currently no ART regimen with 
less than one dose per day. Longer opening hours at the clinic could be considered a 
reasonable improvement. Patients had to leave their daily occupation to come to the CTC in 
the middle of the day, which was more or less complicated for all patients due to travel 
distance, occupation and so on. Side effects could to some extent also be considered 
avoidable, not entirely but by giving low-income countries access to the same types of new 
ART drugs as high-income countries have, since most new drugs have less side effects than 
older drugs. It is an economical question. Something that could be done is to make sure that 
patients experiencing side effects get to try another treatment regimens, since Tanzania have 
different first line and second line treatment combinations to try (although not nearly as many 
as high-income countries). The suggestion to get medicine closer to home will actually be 
fulfilled in year 2018 when ART patients in Tanzania will be offered to get medicine 
delivered to their homes. This has been proven to be a successful intervention for increasing 
retention before (15). 
 
Experience of antiretroviral treatment  
There were 97 patients out of 100 filling in at least one experienced positive effect since start 
of ART, which is a pleasing result. In addition to positive effects, 61/100 patients filled in one 
or more negative effects since ART start. Women experienced weight loss to a higher extent 
than men. One explanation for the greater weight loss in women could be that the drugs are 
prescribed in fixed doses with the same dose for all adults. Women often have lower body 
weight than men and the doses can sometimes be too high for them and result in more adverse 
effects. Adjusting doses after body weight could be successful in lowering side-effects. 
Moreover, patients that stated that they had missed to take medicine at least one time the last 
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four weeks were more likely to experience loss of appetite and headache than patients with no 
missed doses. These patients (that had missed to take doses) also answered that the reason for 
not taking all doses wanted to avoid side effects to a higher extent than patients that had taken 
all doses. As stated before: side effects could be reason enough for nonadherence.  
 
Social support 
When patients were asked about reasons for not informing others about their HIV status a 
high level of stigma remaining in the Tanzanian society could be seen. There were 22/100 
patients stating that they were afraid to be discriminated if their HIV status was revealed, also 
10/100 patients were afraid their families would exclude them. Several previous studies have 
shown that stigma increases the risk of poor adherence to antiretroviral treatment (19, 31, 32). 
Interventions for lowering stigma are necessary, both within the group of HIV positive 
patients and in the rest of society. As long as HIV-related stigma continue to be high it will be 
difficult to reach the 90-90-90 goal; not enough people will be tested neither will adherence to 
treatment be high enough.  
 
Strengths and Weaknesses  
A strength of this study is that it is one of few studies that look into how many HIV patients 
that actually remain in care and treatment and that does not just focus on the patients that are 
still in treatment. Another strength was that there was enough data gathered to actually get 
significant results. There were also three different parts of the study that enlightened different 
aspects.  
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A great limitation to this study is that it was not certain that the patients that had been labelled 
lost to follow-up were in fact lost to follow-up, they could be dead or transferred. This makes 
it impossible to say that the risk factors for becoming lost to follow-up identified in this study 
are risk factors for just leaving care. They are, however, risk factors for becoming lost to 
follow-up where the term included patients that had left care, transferred to another clinic or 
died. This especially applied for the file study (part B), considering part A data was supposed 
be have been adjusted for deaths and transfers.  
 
Another weakness is the design of the questionnaire. There were several questions that lacked 
the alternative “no answer” or that none of the other alternatives applied. This resulted in that 
some questions had low answering frequency, which can be assumed to mean that patients 
thought that none of the alternatives applied, but we cannot know whether it actually was that 
way or just that patients did not answer that question for some other reason. 
 
In addition, another weakness concerning the questionnaire is the question of how many 
medicine doses patients had forgotten to take the last four weeks. The alternatives there were 
none, 1-2, 3-4 etcetera. This makes it impossible to know exactly how many doses patients 
missed and, therefore, we cannot say whether patients had a complete or non-complete 
adherence (incomplete adherence is usually described by more than 5% missed doses). The 
limit would be at more than one for patients taking one dose per day and for patients taking 
two doses per day the limit would be more than two missed doses. Because of this, analyses 
were done with patients divided into groups based on if they had any missed doses or not.   
 
Patients that were not literate were helped with filling in the questionnaire by a nurse. It is 
likely that this lack of privacy and decreased anonymity would affect how patients answer. 
 41 
Also, patients were often sitting close to each other in the waiting room while answering the 
questionnaire which also affected the privacy.  
 
Since parts of this study were retrospective review of patients´ files, it was not possible to 
assess other structural and socioeconomical important predictors for retention, such as 
transports to clinic, income and level of education. There were also missing data in the files, 
for instance CD4 count after one year was only measured in 43% of patients.  
 
Finally, it would have been good to have bigger study populations to increase the power of 
the study.  
 
Further studies 
It would have been interesting to search for patients that have actually left care and treatment 
and ask them about why they left. This is, however, a study that demands more time than this 
study was given.  
 
Also, it would be interesting to see what the results would be like if patients had been divided 
into different outcome categories, such as: retained at original clinic, known transfers, silent 
transfers, deaths in and deaths out of care.  
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Conclusions 
Main conclusions:  
- Retention to care and treatment at Dodoma Regional Referral Hospital was low and 
was decreasing during the years 2012-2015. Efforts need to be made to increase the 
retention. 
- One factor that was linked to non-retention was amongst others having HIV classified 
as WHO clinical stage 3 at treatment start.   
- There were fewer men attending the clinic and men sought help at a later stage. This 
needs to be improved and campaigns need to target men specifically.  
- HIV-related stigma was still high in Tanzania and further actions need to be taken to 
diminish it. As long as there is a high level of stigma HIV will never be sufficiently 
reduced.  
- Side effects can be a sole reason for leaving treatment. There is need to pay thorough 
attention to side effects and to trying to bring them down.  
- By enquiring for factors which has been linked with getting lost to follow-up patients 
with increased risk can be identified and given extra attention.   
 
Future perspectives  
Currently the patients meet a doctor during all their appointments at the Care and Treatment 
Clinic (CTC) at Dodoma Regional Referral Hospital. This results in very short and rapid 
appointments where patients have to be really on toe if they want to ask something or have 
any complaints. It might be better to sparse out these appointments and make them fewer but 
longer. Instead patients could have regular meetings with nurses or other staff at the CTC as 
long as everything is going well and just meet doctors when something concerning the 
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treatment is not going well. Since doctors are the most expensive and limited resource at the 
CTC this could be a way to use the doctors´ time in a meaningful way.  
 
Another suggestion that goes hand in hand with the previous one is to use volunteers that are 
HIV positive themselves. These volunteers could get some education and then work with 
educating new HIV patients or even with having the appointments (between doctors´ 
appointments) at the CTC. This could be a way to gain patients´ trust; knowing that the 
person you talk to actually share your experiences can make it easier to get an honest and 
open conversation.   
 
All in all, these suggestions could lead to more thorough appointments, more efficiency both 
economically and time-wise and finally they could lead to improved adherence and retention 
in treatment.  
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Populärvetenskaplig sammanfattning 
 
Låg andel HIV-positiva patienter kvar i vård vid uppföljning  
på Dodomas regionsjukhus, Tanzania 
 
Det finns bra behandling för HIV-sjuka människor som kallas antiretroviral terapi. För att 
hjälpa måste dock denna behandling tas med stor noggrannhet och det är nödvändigt att ta 
medicin dagligen livet ut. Gör man det beräknas man leva lika länge som en icke HIV-positiv 
person.  
 
Tanzania är ett land som drabbats hårt av HIV, men som på senare år kraftigt har ökat antalet 
patienter som behandlas. Nu är utmaningen att dessa patienter ska fortsätta att komma på 
mottagningsbesök och ta sin behandling och dessutom göra det med den noggrannhet som 
krävs.  
 
Denna studie är utförd i Tanzania och målet med studien var att undersöka hur stor andel av 
de patienter som började med HIV-behandling på Dodomas regionsjukhus från år 2012 till 
2015 som fortfarande går kvar på sjukhuset och tar sina mediciner. Ett annat mål var att 
undersöka om patienter som slutar med behandling på något sätt skiljer sig från de som 
fortsätter. Till slut gjordes även en enkätundersökning där syftet var att ta reda på patienters 
upplevelse av HIV-behandling och vad som kan göras bättre.  
 
Det visade sig att endast 60% av de som började med behandling under 2012–2015 var kvar 
på behandling efter ett år, andelen fortsatte sedan att sjunka och fyra år efter behandlingsstart 
var det bara 47%. Detta är en oväntat låg andel och man måste med största allvar jobba för att 
förbättra detta.  
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Studien visade att de som vid behandlingsstart hade HIV i ett allvarligt stadium (som kallas 
WHO stadium 3) hade ökad risk att lämna behandlingen. Det var också fler av de som slutade 
med behandling som hade upplevt biverkningar av läkemedlen.  
 
Enkätsvar visade att 22% av de svarande patienterna inte talar om för andra att de är HIV-
positiva på grund av att de är rädda för att bli diskriminerade. Vidare angav 10% att de var 
rädda för att bli uteslutna ur sina familjer om deras HIV-status avslöjades. Dessa resultat visar 
på att stigmatisering kopplat till HIV fortfarande är utbrett i Tanzania. Detta är också något 
som behöver jobbas med, både på patientnivå och sett till samhället i stort. Så länge 
stigmatisering är vanligt förekommande kommer det inte att gå att stoppa spridningen av 
HIV.  
 
Genom att efterfråga faktorer som är kopplade till att ha en hög risk för att sluta med 
behandling kan man identifiera vilka patienter som på olika sätt behöver extra insatser och på 
så sätt kan förhoppningsvis avhopp förebyggas. Det är i detta arbete resultaten från denna 
studie kan användas.  
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Abbreviations 
 
AIDS – Acquired Immuno Deficiency Syndrome  
ART – Antiretroviral Treatment 
CTC – Care and Treatment Clinic  
DRRH – Dodoma Regional Referral Hospital 
EI – Entry Inhibitors  
HIV – Human Immunodeficiency Virus 
II – Integrase Inhibitors 
LTFU – Lost to Follow-up 
NNRTI – Non-Nuleoside Reverse Transcriptase Inhibitors 
NRTI – Nucleoside Reverse Transcriptase Inhibitors  
PI – Protease Inhibitors 
PLHIV – People living with HIV 
SSA – Sub-Saharan Africa  
TB – Tuberculosis  
UNAIDS – The Joint United Nations Programme on HIV/AIDS 
WHO – World Health Organization  
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Appendix 
 
Patient questionnaire 
This is a questionnaire about HIV 
treatment which is part of a study about 
what makes patients stay on antiretroviral 
treatment. The questionnaire is anonymous 
and participation is voluntary.  
 
We are grateful for your participation. 
If you have any questions regarding the 
survey, please contact: 
 
Dodoma Regional Referral Hospital 
Jenny Bodell, medical student 
Supervisors: Dr Boniface Nguhuni and Dr 
Siraji Shaban, Dodoma Regional Referral 
Hospital, Prof Rune Andersson, 
Gothenburg University, Sweden. 
  
 
1. Gender: 
□ Female 
□ Male  
 
2. Age (years): ______________ 
3. Marital status 
□ Married  
□ Long term relationship  
□ Single  
□ Divorced  
□ Widower 
 
4. Level of education  
□ Never been to school  
□ Primary school not finished  
□ Primary school  
□ Secondary school 
□ High school 
□ University/College  
 
 
 
 
 
 
 
 
5. Actual social situation 
□ Employed 
□ Self-employed  
□ Not employed  
□ Student  
□ Disability pension  
□ Other grant: ___________________ 
 
6. Religious affiliation 
□ Christian  
□ Muslim  
□ Indigenous religion  
□ No religion  
 
7. When were you diagnosed HIV 
positive? 
Year: ____________________ 
Month: ___________________ 
8. When did you start your HIV 
treatment at this clinic? 
Year: ____________________ 
Month: ___________________ 
9. How many times per day do you take 
your medicine? 
□ One time 
□ Two times 
□ Three times  
□ Others: _________________________ 
 
10. How would you describe your 
general health status? 
 
Very poor  1      2      3      4      5  Excellent 
 
11. How would you describe your 
general health status before starting 
HIV treatment? 
 
Very poor  1      2      3      4      5  Excellent 
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12. How many times did you miss to 
take your medication against HIV the 
last four weeks? 
□ 0 
□ 1-2  
□ 3-4 
□ 5-6 
□ 7-10 
□ More than 10 
13. Have you ever interrupted or 
stopped the HIV treatment? 
□ Yes 
□ No 
 
14. If you ever missed taking your 
medication, what was the reason? (You 
can tick several boxes) 
□ Forgot  
□ Was away from home  
□ Had problems taking the tablets at 
specific times  
□ Ran out of tablets  
□ Could not go to the clinic  
□ Had too many tablets to take/  
□ Felt ill or sick  
□ Felt better  
□ Wanted to avoid side effects  
□ Did not want others to notice me taking 
medication  
□ Someone advised me not to take my 
medication 
□ Other reason: 
__________________________________ 
 
15. What do you think could be done to 
prevent you from missing to take tablets 
or interrupt the HIV treatment? (You 
can tick several boxes) 
□ Fewer tablets 
□ Less side effects  
□ Possibility to get medicine closer to 
home 
□ Less queues at the clinic  
□ Longer opening hours at the clinic  
□ More appointments with a doctor or 
nurse  
□ Better information  
□Other: ________________________ 
16. What will happen if you do not take 
your HIV medicine regularly? 
□ Nothing will happen  
□ I will feel worse 
□ After some time the medicine will no 
longer have any effect  
 
17. Have you experienced any of the 
following positive effects since you 
started HIV treatment? (You can tick 
several boxes) 
□ More energy  
□ Better sleep  
□ Increased appetite 
□ Feeling happier  
□ More interested in sex 
 
18. Have you experienced any of the 
following negative effects since you 
started HIV treatment? (You can tick 
several boxes) 
□ Less energy 
□ Sleeping disturbances 
□ Loss of appetite  
□ Feeling depressed 
□ Less interest in sex  
□ Diarrhoea  
□ Headache  
□ Skin rashes  
□ Losing weight  
□ Thinner face  
□ Slim legs  
□ More abdominal fat  
□ Absent or abnormal sensation in feet  
□ None  
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19. What motivates you to keep taking 
your HIV medication? 
__________________________________
__________________________________
__________________________________
__________________________________
__________________________________
__________________________________
__________________________________ 
 
20. Who have you told that you are HIV 
positive? (You can tick several boxes) 
□ Partner  
□ Mother  
□ Father  
□ Sister or brother  
□ Children  
□ Friends  
□ None 
21. If you choose to not tell other people 
that you are HIV positive, what are your 
reasons? (You can tick several boxes) 
□ I am afraid my partner would leave me  
□ I am afraid my partner would not be 
intimate with me 
□ I am afraid my family would exclude me  
□ I am afraid my friends would exclude 
me  
□ I am afraid I would lose my job  
□ I am afraid I would be discriminated  
□ I feel ashamed that I have HIV 
□ Nobody else needs to know  
□ Other reason: 
__________________________________ 
 
22. Do the people that you informed 
about being HIV positive give you 
support? 
□ Yes  
□ No 
□ More problems than support  
□ I have not informed anybody about my 
HIV status  
□ No answer  
 
Thank you very much for your 
participation. By filling out this 
questionnaire you help us to improve the 
future care of you and other HIV positive 
people. 
 
